The limited armamentarium against drug-resistant Gram-negative bacilli has led to the
development of several novel β-lactam–β-lactamase inhibitor combinations (BLBLIs). In this …

Antimicrobial resistance is one of the major problems in current practical medicine. The
spread of genes coding for resistance determinants among bacteria challenges the use of …

Gram-negative bacteria and their complex cell envelope, which comprises an outer
membrane and an inner membrane, are an important and attractive system for studying the …

Ceftazidime-avibactam (Zavicefta®) is an intravenously administered combination of the
third-generation cephalosporin ceftazidime and the novel, non-β-lactam β-lactamase …

Multidrug resistance (MDR) represents a serious global threat due to the rapid global spread
and limited antimicrobial options for treatment of difficult-to-treat (DTR) infections sustained …

Abstract Objective Ceftazidime–avibactam (CAZ-AVI) is a novel synthetic β-lactamase
inhibitor combination. Although the combination has been available clinically for only a few …

Objectives The aim was to investigate the activity of ceftazidime/avibactam (CAZ/AVI)
against carbapenem-resistant Klebsiella pneumoniae (CRKP) and identify the resistance …

ST11 carbapenem-resistant K. pneumoniae (CRKP) has been the dominant clone in China.
In this review, we trace the prevalence of ST11 CRKP in China Antimicrobial Surveillance …

Carbapenem-resistant hypervirulent Klebsiella pneumoniae (CR-hvKP), a type of Klebsiella
pneumoniae (KP) that exhibits hypervirulence and carbapenem resistance phenotypes, can …

Ceftazidime/avibactam and meropenem/vaborbactam are changing the management of
invasive infections due to carbapenem-resistant Enterobacteriaceae (CRE), leading to …